Medicare AdvantageCoverageMedium impact
MA08.181a, Zolbetuximab-clzb (Vyloy®)
Independence Blue Cross·Oncology·Pharmacy
Effective date
Apr 29, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.181a for Zolbetuximab-clzb (Vyloy®), a specialty pharmacy medication, has been reissued with an effective date of April 29, 2026. This is a future-dated policy update that will impact coverage and billing for this oncology medication.
Action Required
Before April 29, 2026: Billing team should monitor for updated coverage criteria and prior authorization requirements for Zolbetuximab-clzb (Vyloy®) under Medicare Advantage plans. Review the full policy details at the source URL closer to the effective date to understand specific billing and documentation requirements.